Core One Labs Yönetim

Yönetim kriter kontrolleri 2/4

Core One Labs CEO'su Joe Shacker, Jul2020 tarihinde atandı, in görev süresi 4.33 yıldır. şirketin hisselerinin 0.6% doğrudan sahiptir ve bu hisselerin değeri € 27.07K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 3.6 yıldır.

Anahtar bilgiler

Joe Shacker

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.3yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	3.9yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Joe Shacker'un ücretlendirmesi Core One Labs'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	n/a	n/a	-CA$16m
Sep 30 2022	n/a	n/a	-CA$15m
Jun 30 2022	n/a	n/a	-CA$19m
Mar 31 2022	n/a	n/a	-CA$25m
Dec 31 2021	CA$243k	CA$120k	-CA$37m
Sep 30 2021	n/a	n/a	-CA$59m
Jun 30 2021	n/a	n/a	-CA$77m
Mar 31 2021	n/a	n/a	-CA$70m
Dec 31 2020	CA$60k	CA$60k	-CA$47m

Tazminat ve Piyasa: Joe şirketinin toplam tazminatının German pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Joe şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Joe Shacker (33 yo)

4.3yrs

Görev süresi

CA$242,751

Tazminat

Mr. Joel Shacker also known as Joe, is Chief Executive Officer at Core One Labs Inc since July 3, 2020 and has been its Director since May 29, 2020. Mr. Shacker serves as Director at American Future Fuel C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joel Shacker	CEO & Director	4.3yrs	CA$242.75k	0.60% € 27.1k
Geoffrey Balderson	CFO, Secretary & Director	4.3yrs	CA$40.92k	0.079% € 3.5k
Santiago Ferro	Chief Medical Officer & Director	3.5yrs	CA$100.00k	0.89% € 40.0k
Brad Eckenweiler	Founder & Advisor	no data	Veri yok	Veri yok
Jan Burian	Chief Technical Officer	no data	Veri yok	Veri yok
Elizabeth Matthews	Head of Scientific & Regulatory Affairs	3.6yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: LD6 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joel Shacker	CEO & Director	4.5yrs	CA$242.75k	0.60% € 27.1k
Geoffrey Balderson	CFO, Secretary & Director	3.3yrs	CA$40.92k	0.079% € 3.5k
Santiago Ferro	Chief Medical Officer & Director	1.8yrs	CA$100.00k	0.89% € 40.0k
Patrick Morris	Independent Director	4.8yrs	Veri yok	0.17% € 7.5k
Dan Polonenko	Member of Advisory Board	3.6yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LD6 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Core One Labs Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Core One Labs Inc. Announces Management Changes

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Less than half of directors are independent

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Executive Chairman recently sold €55k worth of stock

Recent updates

New major risk - Financial data availability

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

New minor risk - Financial data availability

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

New major risk - Market cap size

New major risk - Shareholder dilution

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Full year 2023 earnings released: CA$0.49 loss per share (vs CA$1.40 loss in FY 2022)

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Less than half of directors are independent

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Executive Chairman recently sold €55k worth of stock

Chief Science Officer & Director John Sanderson has left the company

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Executive Chairman recently sold €65k worth of stock

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş